Once-daily overactive bladder drug shows promise

July 20, 2006

The second of two phase III trials has shown that once-daily trospium chloride (Sanctura XR) reduces frequency of urination and the number of urge incontinence episodes in individuals with a once-daily formulation for the treatment of overactive bladder.

The second of two phase III trials has shown that once-daily trospium chloride (Sanctura XR) reduces frequency of urination and the number of urge incontinence episodes in individuals with overactive bladder.

Both trials in the phase III program were randomized, double-blind, placebo-controlled studies comparing the reduction in the frequency of urination and the reduction in urge urinary incontinence episodes between drug and placebo patients. Compared with placebo recipients, patients treated with once-daily trospium experienced statistically significant improvement in the number of toilet voids per day at the end of the 12-week trial (p=.0009). At week 12, compared with baseline, these same patients had 2.5 fewer toilet voids per day, while placebo patients had 1.8 fewer toilet voids per day.

Patients treated with once-daily trospium also experienced statistically significant improvements in the number of urge urinary incontinence events per day (p<.0001) and in volume voided per void (p=.001) at week 12, compared with placebo patients, according to Indevus Pharmaceuticals, which is developing the drug.